TARGETED PROTEIN DEGRADATION USING PROTAC TECHNOLOGY: OPPORTUNITIES IN MODERN DRUG DEVELOPMENT
Keywords:
PROTAC; targeted protein degradation; ubiquitin–proteasome system; E3 ubiquitin ligase; ternary complex; medicinal chemistry; clinical translation.Abstract
Background:Proteolysis-targeting chimeras (PROTACs) redirect the ubiquitin–proteasome system to eliminate selected disease-associated proteins, providing an event-driven alternative to sustained target inhibition. Objective: To critically assess the molecular rationale, preclinical achievements, clinical evidence and development barriers of PROTAC technology. Methods: A structured narrative synthesis of 15 international peer-reviewed publications (2001–2025) was performed using PubMed records and journal-publisher sources. Evidence was categorized by mechanism, molecular optimization, translational application and study maturity; no original experiments or pooled meta-analysis were conducted. Results: Cooperative ternary-complex formation and E3 ligase recruitment determine degradation potency and selectivity. Preclinical work established degradation of BRD4 and STAT3, whereas early clinical studies demonstrated target engagement for IRAK4 and BTK degraders. In the phase III VERITAC-2 trial, vepdegestrant improved median progression-free survival among patients with ESR1-mutated advanced breast cancer (5.0 versus 2.1 months; hazard ratio 0.58), but the difference was not statistically significant in the overall randomized population. Conclusion: PROTACs offer a credible drug-development strategy for selected intracellular targets; oral exposure, tissue selectivity, resistance and comparative patient benefit remain key validation priorities.
References
1.Sakamoto K. M., Kim K. B., Kumagai A., et al. Protacs: chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation // Proceedings of the National Academy of Sciences USA. — 2001. — Vol. 98, No. 15. — P. 8554–8559. — DOI: 10.1073/pnas.141230798.
2.Bondeson D. P., Mares A., Smith I. E. D., et al. Catalytic in vivo protein knockdown by small-molecule PROTACs // Nature Chemical Biology. — 2015. — Vol. 11. — P. 611–617. — DOI: 10.1038/nchembio.1858.
3.Winter G. E., Buckley D. L., Paulk J., et al. Phthalimide conjugation as a strategy for in vivo target protein degradation // Science. — 2015. — Vol. 348, No. 6241. — P. 1376–1381. — DOI: 10.1126/science.aab1433.
4.Zengerle M., Chan K.-H., Ciulli A. Selective small molecule induced degradation of the BET bromodomain protein BRD4 // ACS Chemical Biology. — 2015. — Vol. 10, No. 8. — P. 1770–1777. — DOI: 10.1021/acschembio.5b00216.
5.Gadd M. S., Testa A., Lucas X., et al. Structural basis of PROTAC cooperative recognition for selective protein degradation // Nature Chemical Biology. — 2017. — Vol. 13, No. 5. — P. 514–521. — DOI: 10.1038/nchembio.2329.
6.Nowak R. P., DeAngelo S. L., Buckley D., et al. Plasticity in binding confers selectivity in ligand-induced protein degradation // Nature Chemical Biology. — 2018. — Vol. 14, No. 7. — P. 706–714. — DOI: 10.1038/s41589-018-0055-y.
7.Bai L., Zhou H., Xu R., et al. A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo // Cancer Cell. — 2019. — Vol. 36, No. 5. — P. 498–511.e17. — DOI: 10.1016/j.ccell.2019.10.002.
8.Békés M., Langley D. R., Crews C. M. PROTAC targeted protein degraders: the past is prologue // Nature Reviews Drug Discovery. — 2022. — Vol. 21. — P. 181–200. — DOI: 10.1038/s41573-021-00371-6.
9.Chirnomas D., Hornberger K. R., Crews C. M. Protein degraders enter the clinic — a new approach to cancer therapy // Nature Reviews Clinical Oncology. — 2023. — Vol. 20. — P. 265–278. — DOI: 10.1038/s41571-023-00736-3.
10.Ackerman L., Acloque G., Bacchelli S., et al. IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial // Nature Medicine. — 2023. — Vol. 29. — P. 3127–3136. — DOI: 10.1038/s41591-023-02635-7.
11.Montoya S., Bourcier J., Noviski M., et al. Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127 // Science. — 2024. — Vol. 383, No. 6682. — Article eadi5798. — DOI: 10.1126/science.adi5798.
12.Tsai J. M., Nowak R. P., Ebert B. L., Fischer E. S. Targeted protein degradation: from mechanisms to clinic // Nature Reviews Molecular Cell Biology. — 2024. — Vol. 25. — P. 740–757. — DOI: 10.1038/s41580-024-00729-9.
13.Zhong G., Chang X., Xie W., et al. Targeted protein degradation: advances in drug discovery and clinical practice // Signal Transduction and Targeted Therapy. — 2024. — Vol. 9. — Article 308. — DOI: 10.1038/s41392-024-02004-x.
14.Hinterndorfer M., Spiteri V. A., Ciulli A., Winter G. E. Targeted protein degradation for cancer therapy // Nature Reviews Cancer. — 2025. — Vol. 25. — P. 493–516. — DOI: 10.1038/s41568-025-00817-8.
15.Campone M., De Laurentiis M., Jhaveri K., et al. Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer // New England Journal of Medicine. — 2025. — Vol. 393, No. 6. — P. 556–568. — DOI: 10.1056/NEJMoa2505725.
